Jump to content

Multidrug-resistant Clostridioides difficile

From WikiProjectMed
Multidrug-resistant Clostridioides difficile
Other names: MDR C. difficile[1]
SpecialtyInfectious disease
SymptomsWatery diarrhea,fever,loss of appetite,nausea[4]
ComplicationsPseudomembranous colitis, toxic megacolon[5]
Risk factorsOveruse/prolonged use of antibiotics, PPI[6][7]
Diagnostic methodAntibiotic susceptibility testing[8]
TreatmentVancomycin and fidaxomicin may work,Fecal microbiota transplant[8][9]

Multidrug-resistant Clostridioides difficile is a bacterium that has developed resistance to many antibiotics, making infections harder to treat. This bacterium can cause severe diarrhea and colitis . It often affects individuals who have recently used antibiotics or have been hospitalized, as these environments can disrupt the normal gut microbiota and allow C. difficile to occur.[10][2]

Ribotype 027 is a highly virulent strain of Clostridioides difficile associated with severe infections and outbreaks, particularly in healthcare settings, additionally, ribotype 027 has developed resistance to fluoroquinolone antibiotics.[8][11]

Signs and symptoms

Abdominal pain

In terms of symptoms of Multidrug-resistant Clostridioides difficile infection are generally the same as those of non-resistant C. difficile infections. [4]

The difference with multidrug-resistant strains is that they are harder to treat because many common antibiotics are not effective against them, hence here are some of the symptoms:[4]

  • Watery diarrhea
  • Loss of appetite
  • Abdominal pain

Risk factor

PPIs work on the parietal cells in stomach and irreversibly inhibit gastric hydrogen potassium ATPase[12]

In terms of the risk factors that could facilitate CDI drug(multi drug)-resistance we find:[6][7]

  • Overuse/prolonged use of antibiotics can disrupt the gut microbiome
  • Healthcare settings increase exposure to resistant strains

Mechanism

In terms of the mechanism of CDI we find that use of systemic antibiotics, including broad-spectrum penicillins/cephalosporins, fluoroquinolones, and clindamycin, causes the normal microbiota of the bowel to be altered. The antibiotic kills off other competing bacteria in the intestine, any bacteria remaining will have less competition for space and nutrients. The net effect is to permit more extensive growth than normal of certain bacteria. C. difficile is one such type of bacterium. In addition to proliferating in the bowel, C. difficile also produces toxins.Toxin A (TcdA) and Toxin B (TcdB) are the primary virulence factors in Clostridium difficile infection .[13][5]

MDR

Now then in terms of the specific MDR part of the infection we find that modifications are obtained via horizontal gene transfer or mutation, hence the primary mechanisms by which C. difficile achieves multidrug resistance :[14][8]

  • The antibiotic works by binding to a specific target molecule within the bacterial cell . MDR can occur if this target changes shape slightly, so the antibiotic can no longer bind effectively, rendering the drug useless. An example like Ciprofloxacin or Levofloxacin drugs target DNA gyrase, subunits GyrA and GyrB, an enzyme important for DNA replication. Specific point mutations in the gyrA or gyrB genes alter the enzyme structure, preventing the fluoroquinolone from binding and inhibiting it.[8][15][1]
  • Enzymatic inactivation, thats to say the bacterium produces enzymes that specifically attack and break down the antibiotic molecule before it can reach its target. Production of chloramphenicol acetyltransferases,encoded by genes like catD, adds an acetyl group to the drug, inactivating it.[8][16][17][2]

Diagnosis

Stool sample

As to the diagnosis of multidrug-resistant CDI involves a combination of clinical assessment, stool tests, and antibiotic susceptibility testing.[2]

Two-step algorithm:[5]

  • Screening for C. difficile done through GDH assays or NAATs
  • If the initial screening test is positive, follow up is with enzyme immunoassays to detect toxins A and B.

Antibiotic susceptibility testing for MDR C. difficile helps identify resistance mechanisms and guides in selecting appropriate antibiotics. Laboratories use agar dilution, broth microdilution, and E-test, to assess antibiotic susceptibility[8]

Treatment

In terms of Multidrug-resistant Clostridioides difficile infections are difficult to treat due to resistance to multiple antibiotics. However, there are still options available:[8][9]

Epidemiology

As to the epidemiology of MDR C. difficile we find that it has seen a significant increase in incidence and severity worldwide, the emergence of hypervirulent strains, such as ribotype 027, has contributed to this. While considered a healthcare-associated infection , theres a growing prevalence of community-associated MDR C. difficile.[20][21][22]

History

In terms of history we find that John Bartlett is credited with discovering Clostridioides difficile in 1975. The understanding of antibiotic resistance in C. difficille, including the emergence of strains with resistance to multiple antibiotics, developed over time.[23]

Notes

1.^ Some sources in mechanism section are not Pubmed indexed reviews

References

  1. ↑ Spigaglia, Patrizia; Mastrantonio, Paola; Barbanti, Fabrizio (2018). "Antibiotic Resistances of Clostridium difficile". Updates on Clostridium difficile in Europe: Advances in Microbiology, Infectious Diseases and Public Health Volume 8. Advances in Experimental Medicine and Biology. Vol. 1050. Springer International Publishing. pp. 137–159. doi:10.1007/978-3-319-72799-8_9. ISBN 978-3-319-72799-8. PMID 29383668.
  2. ↑ 2.0 2.1 2.2 Markantonis, John E.; Fallon, John T.; Madan, Rajat; Alam, Md Zahidul (27 January 2024). "Clostridioides difficile Infection: Diagnosis and Treatment Challenges". Pathogens (Basel, Switzerland). 13 (2): 118. doi:10.3390/pathogens13020118. ISSN 2076-0817. PMC 10891949. PMID 38392856.
  3. ↑ Mengoli, Mariachiara; Barone, Monica; Fabbrini, Marco; D'Amico, Federica; Brigidi, Patrizia; Turroni, Silvia (24 November 2022). "Make It Less difficile: Understanding Genetic Evolution and Global Spread of Clostridioides difficile". Genes. 13 (12): 2200. doi:10.3390/genes13122200. ISSN 2073-4425. PMC 9778335. PMID 36553467.
  4. ↑ 4.0 4.1 4.2 "C. diff Infections". medlineplus.gov. Retrieved 16 April 2025.
  5. ↑ 5.0 5.1 5.2 Mada, Pradeep Kumar; Alam, Mohammed U. (2025). "Clostridioides difficile infection". StatPearls. StatPearls Publishing. PMID 28613708.
  6. ↑ 6.0 6.1 Azzini, Anna Maria; Be, Giorgia; Naso, Laura; Lambertenghi, Lorenza; Salerno, Nicola Duccio; Coledan, Ilaria; Bazaj, Alda; Mirandola, Massimo; Miotti, Jessica; Mazzaferri, Fulvia; Accordini, Simone; Lo Cascio, Giuliana; Tacconelli, Evelina (12 June 2023). "Risk factors for colonization with multidrug-resistant Gram-negative bacteria and Clostridioides difficile in Long Term Care Facilities (LTCFs) residents: the evidence from 27 facilities in a high endemic setting". Frontiers in Cellular and Infection Microbiology. 13. doi:10.3389/fcimb.2023.1155320. ISSN 2235-2988. PMC 10292821. PMID 37377644.
  7. ↑ 7.0 7.1 Tariq, Raseen; Singh, Siddharth; Gupta, Arjun; Pardi, Darrell S.; Khanna, Sahil (1 June 2017). "Association of Gastric Acid Suppression With Recurrent Clostridium difficile Infection: A Systematic Review and Meta-analysis". JAMA Internal Medicine. 177 (6): 784–791. doi:10.1001/jamainternmed.2017.0212. ISSN 2168-6106. PMID 28346595. Archived from the original on 1 March 2024. Retrieved 20 April 2025. Archived 1 March 2024 at the Wayback Machine
  8. ↑ 8.0 8.1 8.2 8.3 8.4 8.5 8.6 8.7 Peng, Zhong; Jin, Dazhi; Kim, Hyeun Bum; Stratton, Charles W.; Wu, Bin; Tang, Yi-Wei; Sun, Xingmin (23 June 2017). "Update on Antimicrobial Resistance in Clostridium difficile: Resistance Mechanisms and Antimicrobial Susceptibility Testing". Journal of Clinical Microbiology. 55 (7): 1998–2008. doi:10.1128/jcm.02250-16. PMC 5483901. PMID 28404671.
  9. ↑ 9.0 9.1 McDonald, L. Clifford; Gerding, Dale N.; Johnson, Stuart; Bakken, Johan S.; Carroll, Karen C.; Coffin, Susan E.; Dubberke, Erik R.; Garey, Kevin W.; Gould, Carolyn V.; Kelly, Ciaran; Loo, Vivian; Shaklee Sammons, Julia; Sandora, Thomas J.; Wilcox, Mark H. (19 March 2018). "Clinical Practice Guidelines for Clostridium difficile Infection in Adults and Children: 2017 Update by the Infectious Diseases Society of America (IDSA) and Society for Healthcare Epidemiology of America (SHEA)". Clinical Infectious Diseases: An Official Publication of the Infectious Diseases Society of America. 66 (7): e1 – e48. doi:10.1093/cid/cix1085. ISSN 1537-6591. PMC 6018983. PMID 29462280.
  10. ↑ "FAQs: Multidrug-Resistant Organism & Clostridioides difficile Infection (MDRO & CDI) | NHSN | CDC". www.cdc.gov. 31 December 2024. Retrieved 10 April 2025.
  11. ↑ Fatima, Rawish; Aziz, Muhammad (29 January 2019). "The Hypervirulent Strain of Clostridium Difficile: NAP1/B1/027 - A Brief Overview". Cureus. 11 (1): e3977. doi:10.7759/cureus.3977. ISSN 2168-8184. PMC 6440555. PMID 30967977.
  12. ↑ "Goodman & Gilman's: The Pharmacological Basis of Therapeutics, 13e". McGraw Hill Medical. Retrieved 22 June 2025.
  13. ↑ Kuehne SA, Cartman ST, Heap JT, Kelly ML, Cockayne A, Minton NP (October 2010). "The role of toxin A and toxin B in Clostridium difficile infection" (PDF). Nature. 467 (7316): 711–3. Bibcode:2010Natur.467..711K. doi:10.1038/nature09397. hdl:10044/1/15560. PMID 20844489. S2CID 4417414. Archived (PDF) from the original on 9 August 2017. Retrieved 2 September 2019. Archived 9 August 2017 at the Wayback Machine
  14. ↑ Wickramage, Ishani; Spigaglia, Patrizia; Sun, Xingmin (12 November 2021). "Mechanisms of antibiotic resistance of Clostridioides difficile". The Journal of Antimicrobial Chemotherapy. 76 (12): 3077–3090. doi:10.1093/jac/dkab231. ISSN 1460-2091. PMC 8598299. PMID 34297842.
  15. ↑ Spigaglia, Patrizia; Barbanti, Fabrizio; Louie, Thomas; Barbut, Frédéric; Mastrantonio, Paola (June 2009). "Molecular analysis of the gyrA and gyrB quinolone resistance-determining regions of fluoroquinolone-resistant Clostridium difficile mutants selected in vitro". Antimicrobial Agents and Chemotherapy. 53 (6): 2463–2468. doi:10.1128/AAC.01252-08. ISSN 1098-6596. PMC 2687229. PMID 19364867.
  16. ↑ "UniProt". UniProt. Retrieved 19 April 2025.
  17. ↑ Mullany, Peter; Allan, Elaine; Roberts, Adam P. (May 2015). "Mobile genetic elements in Clostridium difficile and their role in genome function". Research in Microbiology. 166 (4): 361–367. doi:10.1016/j.resmic.2014.12.005. ISSN 1769-7123. PMC 4430133. PMID 25576774.
  18. ↑ Su, Grace L.; Ko, Cynthia W.; Bercik, Premysl; Falck-Ytter, Yngve; Sultan, Shahnaz; Weizman, Adam V.; Morgan, Rebecca L. (1 August 2020). "AGA Clinical Practice Guidelines on the Role of Probiotics in the Management of Gastrointestinal Disorders". Gastroenterology. 159 (2): 697–705. doi:10.1053/j.gastro.2020.05.059. ISSN 0016-5085. PMID 32531291. Archived from the original on 6 April 2025. Retrieved 17 April 2025.
  19. ↑ Preidis, Geoffrey A.; Weizman, Adam V.; Kashyap, Purna C.; Morgan, Rebecca L. (1 August 2020). "AGA Technical Review on the Role of Probiotics in the Management of Gastrointestinal Disorders". Gastroenterology. 159 (2): 708–738.e4. doi:10.1053/j.gastro.2020.05.060. ISSN 0016-5085. PMC 8018518. PMID 32531292. Archived from the original on 21 June 2020. Retrieved 17 April 2025.
  20. ↑ Shirley, Debbie-Ann; Tornel, William; Warren, Cirle A.; Moonah, Shannon (10 August 2023). "Clostridioides difficile Infection in Children: Recent Updates on Epidemiology, Diagnosis, Therapy". Pediatrics. 152 (3): e2023062307. doi:10.1542/peds.2023-062307. ISSN 0031-4005. PMC 10471512. PMID 37560802.
  21. ↑ Ptaszyńska, Agata; Macieja, Anna; Rosińska-Lewandoska, Dominika; Bielec, Filip; Machnicki, Piotr; Brauncajs, Małgorzata; Pastuszak-Lewandoska, Dorota (21 February 2025). "Molecular Epidemiology of Clostridioides difficile Infections in Patients Hospitalized in 2017-2019 at the Central Teaching Hospital of Medical University of Lodz, Central Poland". Antibiotics (Basel, Switzerland). 14 (3): 219. doi:10.3390/antibiotics14030219. ISSN 2079-6382. PMC 11939216. PMID 40149031.
  22. ↑ Liu, Crystal; Monaghan, Tanya; Yadegar, Abbas; Louie, Thomas; Kao, Dina (1 July 2023). "Insights into the Evolving Epidemiology of Clostridioides difficile Infection and Treatment: A Global Perspective". Antibiotics (Basel, Switzerland). 12 (7): 1141. doi:10.3390/antibiotics12071141. ISSN 2079-6382. PMC 10376792. PMID 37508237.
  23. ↑ Gorbach, Sherwood L. (15 September 2014). "John G. Bartlett: Contributions to the Discovery of Clostridium difficile Antibiotic-Associated Diarrhea". Clinical Infectious Diseases. 59 (suppl_2): S66 – S70. doi:10.1093/cid/ciu419. ISSN 1058-4838. PMID 25151480.

Further reading

Retrieved from "https://mdwiki.org/w/index.php?title=Multidrug-resistant_Clostridioides_difficile&oldid=1479218"